William Blair Lifts Earnings Estimates for Axon Enterprise

Axon Enterprise, Inc (NASDAQ:AXON) – Equities research analysts at William Blair raised their Q2 2026 earnings estimates for Axon Enterprise in a research report issued on Tuesday, August 5th. William Blair analyst J. Ho now forecasts that the biotechnology company will post earnings of $0.24 per share for the quarter, up from their prior estimate of $0.16. The consensus estimate for Axon Enterprise’s current full-year earnings is $5.80 per share.

AXON has been the subject of several other research reports. Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the company an “overweight” rating in a research note on Friday, July 11th. Northland Securities set a $800.00 target price on shares of Axon Enterprise in a research note on Tuesday. JMP Securities boosted their target price on shares of Axon Enterprise from $725.00 to $825.00 and gave the company a “market outperform” rating in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th. Finally, Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus price target of $837.69.

Axon Enterprise Stock Down 3.3%

AXON stock opened at $842.50 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.62. Axon Enterprise has a 1-year low of $346.71 and a 1-year high of $885.91. The firm has a fifty day moving average price of $774.27 and a two-hundred day moving average price of $665.08. The firm has a market cap of $66.14 billion, a price-to-earnings ratio of 208.02, a PEG ratio of 93.35 and a beta of 1.36.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the previous year, the firm earned $1.20 earnings per share. The business’s revenue was up 32.6% compared to the same quarter last year.

Insider Activity at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of Axon Enterprise stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $738.84, for a total value of $960,492.00. Following the completion of the transaction, the director directly owned 4,829 shares of the company’s stock, valued at $3,567,858.36. The trade was a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brittany Bagley sold 3,400 shares of Axon Enterprise stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the transaction, the chief financial officer directly owned 131,833 shares of the company’s stock, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,642 shares of company stock valued at $25,090,528. Insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC grew its position in shares of Axon Enterprise by 53.0% during the 2nd quarter. Kingsview Wealth Management LLC now owns 621 shares of the biotechnology company’s stock worth $514,000 after buying an additional 215 shares during the period. Citizens Financial Group Inc. RI grew its position in shares of Axon Enterprise by 50.1% during the 2nd quarter. Citizens Financial Group Inc. RI now owns 593 shares of the biotechnology company’s stock worth $491,000 after buying an additional 198 shares during the period. Avantax Advisory Services Inc. grew its position in shares of Axon Enterprise by 1.4% during the 2nd quarter. Avantax Advisory Services Inc. now owns 6,310 shares of the biotechnology company’s stock worth $5,225,000 after buying an additional 86 shares during the period. Cetera Investment Advisers grew its position in shares of Axon Enterprise by 48.7% during the 2nd quarter. Cetera Investment Advisers now owns 33,469 shares of the biotechnology company’s stock worth $27,710,000 after buying an additional 10,959 shares during the period. Finally, Creative Planning grew its position in shares of Axon Enterprise by 7.9% during the 2nd quarter. Creative Planning now owns 21,549 shares of the biotechnology company’s stock worth $17,841,000 after buying an additional 1,572 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.